SCHEMBL2476493

SCHEMBL2476493

O=Cc1ccccc1-c1noc2cnccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.36
ESR2 Q92731 5/20 0.36
CYP17A1 P05093 2/20 0.36
CYP1A2 P05177 1/20 0.36
EPHX2 P34913 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
THRB P10828 1/20 0.34
BLM P54132 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
F10 P00742 1/20 0.32
F7 P08709 1/20 0.32
F3 P13726 1/20 0.32
XDH P47989 1/20 0.32
ERN1 O75460 1/20 0.32
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2478126 0.88 CYP17A1 (0.39) ESR1ESR2CYP17A1CYP1A2EPHX2
SCHEMBL6711107 0.83 ESR1 (0.50) ESR1ESR2KMT2AMEN1LMNA
SCHEMBL6711117 0.75 ESR1 (0.44) ESR1ESR2KMT2ATDP1ERN1
SCHEMBL933527 0.75 ESR1 (0.44) ESR1ESR2ERN1
SCHEMBL26982067 0.75 ESR1 (0.44) ESR1ESR2KMT2AMEN1ALDH1A1
SCHEMBL6712641 0.75 ESR1 (0.44) ESR1ESR2KMT2AMEN1MAOB
SCHEMBL6716752 0.72 PTPN1 (0.44) ESR1ESR2KMT2AMEN1LMNA
SCHEMBL7561119 0.72 EPHX2 (0.45) ESR1ESR2EPHX2ALDH1A1SMN1; SMN2
SCHEMBL933957 0.72 ESR1 (0.45) ESR1ESR2KMT2AMEN1ALDH1A1
SCHEMBL13659537 0.72 MAOA (0.48) KMT2AMEN1LMNATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
US-20040229910-A1 Therapeutic compounds N.V. ORGANON (NL) 2004-11-18 US disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229910-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ESR1 2865/4885ESR2 1589/4885CYP17A1 3319/4885
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ESR1 2865/4885ESR2 1589/4885CYP17A1 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.